O’Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151–167 (2019).

Article  PubMed  Google Scholar 

Li, X. et al. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat. Rev. Cancer 21, 541–557 (2021).

Article  CAS  PubMed  Google Scholar 

Tsilimigras, D. I. et al. Liver metastases. Nat. Rev. Dis. Primers 7, 27 (2021).

Article  PubMed  Google Scholar 

Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. 27, 152–164 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, C. et al. Clinical response to immunotherapy targeting programmed cell death receptor 1/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases. JAMA Netw. Open 4, e2118416 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Zeng, Z. et al. CRIg functions as a macrophage pattern recognition receptor to directly bind and capture blood-borne Gram-positive bacteria. Cell Host Microbe 20, 99–106 (2016).

Article  CAS  PubMed  Google Scholar 

Zeng, Z. et al. Sex-hormone-driven innate antibodies protect females and infants against EPEC infection. Nat. Immunol. 19, 1100–1111 (2018).

Article  CAS  PubMed  Google Scholar 

Li, J. et al. The ligation between ERMAP, galectin-9 and dectin-2 promotes Kupffer cell phagocytosis and antitumor immunity. Nat. Immunol. 24, 1813–1824 (2023).

Article  CAS  PubMed  Google Scholar 

Kimura, Y. et al. The innate immune receptor dectin-2 mediates the phagocytosis of cancer cells by Kupffer cells for the suppression of liver metastasis. Proc. Natl Acad. of Sci. USA 113, 14097–14102 (2016).

Article  CAS  Google Scholar 

Dupaul-Chicoine, J. et al. The NLRP3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity 43, 751–763 (2015).

Article  CAS  PubMed  Google Scholar 

Deng, Z. et al. The nuclear factor ID3 endows macrophages with a potent anti-tumour activity. Nature 626, 864–873 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thomson, A. W. & Knolle, P. A. Antigen-presenting cell function in the tolerogenic liver environment. Nat. Rev. Immunol. 10, 753–766 (2010).

Article  CAS  PubMed  Google Scholar 

Zhou, X., Khan, S., Huang, D. & Li, L. V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy. Front. Immunol. 13, 938470 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Helmy, K. Y. et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124, 915–927 (2006).

Article  CAS  PubMed  Google Scholar 

Vogt, L. et al. VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J. Clin. Invest. 116, 2817–2826 (2006).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan, X., Yang, B.-H., Dong, Y., Yamamura, A. & Fu, W. CRIg, a tissue-resident macrophage specific immune checkpoint molecule, promotes immunological tolerance in NOD mice, via a dual role in effector and regulatory T cells. eLife 6, e29540 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Widyagarini, A., Nishii, N., Kawano, Y., Zhang, C. & Azuma, M. VSIG4/CRIg directly regulates early CD8+ T cell activation through its counter-receptor in a narrow window. Biochem. Biophys. Res. Commun. 614, 100–106 (2022).

Article  CAS  PubMed  Google Scholar 

Liu, B. et al. The biology of VSIG4: implications for the treatment of immune-mediated inflammatory diseases and cancer. Cancer Lett. 553, 215996 (2023).

Article  CAS  PubMed  Google Scholar 

Jung, K. et al. VSIG4-expressing tumor-associated macrophages impair anti-tumor immunity. Biochem. Biophys. Res. Commun. 628, 18–24 (2022).

Article  CAS  PubMed  Google Scholar 

Liu, W. et al. In situ expansion and reprogramming of Kupffer cells elicit potent tumoricidal immunity against liver metastasis. J. Clin. Invest. 133, e157937 (2023).

Benechet, A. P. et al. Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature 574, 200–205 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

You, Q., Cheng, L., Kedl, R.M. & Ju, C. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology 48, 978–990 (2008).

Luri-Rey, C. et al. Cross-priming in cancer immunology and immunotherapy. Nat. Rev. Cancer 25, 249–273 (2025).

Article  CAS  PubMed  Google Scholar 

Hildner, K. et al. BATF3 deficiency reveals a critical role for CD8α+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097–1100 (2008).

Albacker, L. A. et al. TIM-4, a receptor for phosphatidylserine, controls adaptive immunity by regulating the removal of antigen-specific T cells. J. Immunol. 185, 6839–6849 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tolcher, A. W. et al. A phase 1/2 dose escalation/expansion study of OR2805 alone or in combination in subjects with advanced solid tumors. J. Clin. Oncol. 40, TPS2693 (2022).

Article  Google Scholar 

Li, J. et al. VSIG4 inhibits proinflammatory macrophage activation by reprogramming mitochondrial pyruvate metabolism. Nat. Commun. 8, 1322 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Huang, X. et al. VSIG4 mediates transcriptional inhibition of NLRP3 and IL-1β in macrophages. Sci. Adv. 5, eaau7426 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Voisinne, G., Gonzalez de Peredo, A. & Roncagalli, R. CD5, an undercover regulator of TCR signaling. Front. Immunol. 9, 2900 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alotaibi, F. et al. CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicity. Eur. J. Immunol. 50, 695–704 (2020).

Article  CAS  PubMed  Google Scholar 

Friedlein, G. et al. Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. J. Immunol. 178, 6821–6827 (2007).

Voisinne, G. et al. Co-recruitment analysis of the Cbl and Cbl-b signalosomes in primary T cells identifies CD5 as a key regulator of TCR-induced ubiquitylation. Mol. Syst. Biol. 12, 876 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Thien, C. B. F. & Langdon, W. Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2, 294–307 (2001).

Article  CAS  PubMed  Google Scholar 

Tsai, Y.-L. et al. TCR signaling promotes formation of an STS1–Cbl-b complex with pH-sensitive phosphatase activity that suppresses T cell function in acidic environments. Immunity 56, 2682–2698 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou, J. et al. The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. Nat. Immunol. 22, 460–470 (2021).

Article